Literature DB >> 5564395

Functional evaluation of an inherited abnormal fibrinogen: fibrinogen "Baltimore".

E A Beck, J R Shainoff, A Vogel, D P Jackson.   

Abstract

The rate of clotting and the rate of development and degree of turbidity after addition of thrombin to plasma or purified fibrinogen from a patient with fibrinogen Baltimore was delayed when compared with normal, especially in the presence of low concentrations of thrombin. Optimal coagulation and development of translucent, rather than opaque, clots occurred at a lower pH with the abnormal fibrinogen than with normal. Development of turbidity during clotting of the abnormal plasma or fibrinogen was less than normal at each pH tested, but was maximal in both at approximately pH 6.4. The physical quality of clots formed from fibrinogen Baltimore was abnormal, as demonstrated by a decreased amplitude on thromboelastography. The morphologic appearance of fibrin strands formed from fibrinogen Baltimore by thrombin at pH 7.4 was abnormal when examined by phase contrast or electron microscopy, but those formed by thrombin at pH 6.4 or by thrombin and calcium chloride were similar to, though less compact, than normal fibrin. The periodicity of fibrin formed from fibrinogen Baltimore was similar to normal and was 231-233 A.A study of the release of the fibrinopeptides from the patient's fibrinogen and its chromatographic subfractions verified the existence of both a normally behaving and a defective form of fibrinogen in the patient's plasma. The defective form differed from normal in three functionally different ways: (a) the rate of release of fibrinopeptides A and AP was slower than normal; (b) no visible clot formation accompanied either partial or complete release of the fibrinopeptides from the defective form in 0.3 M NaCl at pH 7.4; and (c) the defective component possessed a high proportion of phosphorylated, relative to nonphosphorylated, fibrinopeptide A, while the coagulable component contained very little of the phosphorylated peptide (AP). The high phosphate content of the defective component did not appear to be the cause of the abnormality, but may be the result of an associated metabolic or genetic phenomenon.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5564395      PMCID: PMC292114          DOI: 10.1172/JCI106680

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  Studies on the degradation of human fibrinogen by plasmin and trypsin.

Authors:  E A Beck; D P Jackson
Journal:  Thromb Diath Haemorrh       Date:  1966-12-01

2.  The fine structure of fibrin.

Authors:  D Kay; B J Cuddigan
Journal:  Br J Haematol       Date:  1967-05       Impact factor: 6.998

3.  N-terminal disulphide knot of human fibrinogen.

Authors:  B Blombäck; M Blombäck; A Henschen; B Hessel; S Iwanaga; K R Woods
Journal:  Nature       Date:  1968-04-13       Impact factor: 49.962

4.  A new inherited coagulation disorder caused by an abnormal fibrinogen ('fibrinogen Baltimore').

Authors:  E A Beck; P Charache; D P Jackson
Journal:  Nature       Date:  1965-10-09       Impact factor: 49.962

5.  Congenital disorders of fibrinogen.

Authors:  D P Jackson; E A Beck; P Charache
Journal:  Fed Proc       Date:  1965 Jul-Aug

6.  Inherited fibrinogen abnormality causing thrombophilia.

Authors:  O Egeberg
Journal:  Thromb Diath Haemorrh       Date:  1967-02-28

7.  The pattern of inheritance of defective fibrinase (Factor 13).

Authors:  J W Hampton; G R Cunningham; R M Bird
Journal:  J Lab Clin Med       Date:  1966-06

8.  Stable complex of fibrinogen and fibrin.

Authors:  T Sasaki; I H Page; J R Shainoff
Journal:  Science       Date:  1966-05-20       Impact factor: 47.728

9.  Familial disturbance of fibrin monomer aggregation.

Authors:  A Von Felten; F Duckert; P G Frick
Journal:  Br J Haematol       Date:  1966-11       Impact factor: 6.998

10.  Fibrinogen Detroit--a molecular defect in the N-terminal disulphide knot of human fibrinogen?

Authors:  M Blombäck; B Blombäck; E F Mammen; A S Prasad
Journal:  Nature       Date:  1968-04-13       Impact factor: 49.962

View more
  7 in total

1.  Defective alpha-polymerization in the conversion of fibrinogen Baltimore to fibrin.

Authors:  C H Brown; M F Crowe
Journal:  J Clin Invest       Date:  1975-06       Impact factor: 14.808

2.  Congenital dysfibrinogenemias: molecular abnormalities of fibrinogen.

Authors:  E F Mammen
Journal:  Blut       Date:  1976-10

3.  Molecular deficiencies of human blood coagulation.

Authors:  E A Beck
Journal:  Experientia       Date:  1972-01-15

4.  [Quantitative electron microscopic studies on fibrin structure in dysfibrinogenemia].

Authors:  W Krause; P Zimmermann
Journal:  Klin Wochenschr       Date:  1972-06-01

5.  Fibrinogen Philadelphia. A hereditary hypodysfibrinogenemia characterized by fibrinogen hypercatabolism.

Authors:  J Martinez; R R Holburn; S S Shapiro; A J Erslev
Journal:  J Clin Invest       Date:  1974-02       Impact factor: 14.808

6.  Fibrinogen Cleveland II. An abnormal fibrinogen with defective release of fibrinopeptide A.

Authors:  E D Crum; J R Shainoff; R C Graham; O D Ratnoff
Journal:  J Clin Invest       Date:  1974-05       Impact factor: 14.808

Review 7.  Heterogeneity of Genotype-Phenotype in Congenital Hypofibrinogenemia-A Review of Case Reports Associated with Bleeding and Thrombosis.

Authors:  Monika Brunclikova; Tomas Simurda; Jana Zolkova; Miroslava Sterankova; Ingrid Skornova; Miroslava Dobrotova; Zuzana Kolkova; Dusan Loderer; Marian Grendar; Jan Hudecek; Jan Stasko; Peter Kubisz
Journal:  J Clin Med       Date:  2022-02-18       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.